
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
---|---|---|---|---|---|---|
09/30/2025 | Q3 | $1.9M | -- | -- | -$0.03 | -- |
08/08/2025 | Q2 | $1.5M | -- | -- | -$0.03 | -- |
05/13/2025 | Q1 | $1.7M | $1.5M | -$0.02 | -$0.03 | $0.01 |
03/10/2025 | Q4 | $1.6M | $2.9M | -$0.01 | -$0.03 | $0.02 |
11/14/2024 | Q3 | $886.6K | $3.8M | -$0.02 | -$0.03 | $0.01 |
08/08/2024 | Q2 | $786K | $1.4M | -$0.03 | -$0.04 | $0.01 |
05/09/2024 | Q1 | $1.4M | $1.4M | -$0.04 | -$0.04 | -- |
03/07/2024 | Q4 | $2.8M | $2.1M | -$0.02 | -$0.05 | $0.03 |
11/09/2023 | Q3 | -- | -- | -$0.04 | -$0.03 | -$0.01 |
08/10/2023 | Q2 | -- | -- | -$0.03 | -$0.04 | $0.01 |
05/11/2023 | Q1 | -- | -- | -$0.03 | -$0.05 | $0.02 |
03/09/2023 | Q4 | -- | -- | -$0.03 | -$0.04 | $0.01 |
11/10/2022 | Q3 | -- | -- | -$0.04 | -$0.04 | -- |
08/11/2022 | Q2 | -- | -- | -$0.04 | -$0.02 | -$0.02 |
05/12/2022 | Q1 | -- | -- | -$0.04 | -$0.06 | $0.02 |
03/10/2022 | Q4 | -- | -- | -$0.17 | -$0.05 | -$0.12 |
11/10/2021 | Q3 | -- | -- | -$0.05 | -$0.05 | -$0.00 |
08/12/2021 | Q2 | -- | -- | -$0.03 | -$0.04 | $0.01 |
05/13/2021 | Q1 | -- | -- | -$0.01 | -$0.05 | $0.04 |
03/11/2021 | Q4 | -- | -- | $0.01 | -$0.04 | $0.05 |
11/04/2020 | Q3 | -- | -- | -$0.05 | -$0.04 | -$0.01 |
08/06/2020 | Q2 | -- | -- | -$0.04 | -$0.05 | $0.01 |
05/07/2020 | Q1 | -- | -- | -$0.06 | -- | -- |
03/12/2020 | Q4 | -- | -- | -$0.03 | -$0.05 | $0.02 |
11/12/2019 | Q3 | -- | -- | -$0.11 | -$0.05 | -$0.06 |
08/08/2019 | Q2 | -- | -- | -$0.20 | -$0.06 | -$0.15 |
05/09/2019 | Q1 | -- | -- | $0.30 | -$0.06 | $0.36 |
03/14/2019 | Q4 | -- | -- | -$0.35 | -$0.07 | -$0.28 |
11/08/2018 | Q3 | -- | -- | $0.53 | -$0.07 | $0.60 |
08/02/2018 | Q2 | -- | -- | -$0.03 | -- | -- |
05/10/2018 | Q1 | -- | -- | -$0.50 | -- | -- |
03/15/2018 | Q4 | -- | -- | -$0.64 | -- | -- |
11/09/2017 | Q3 | -- | -- | $0.12 | -- | -- |
08/02/2017 | Q2 | -- | -- | -$0.11 | -- | -- |
05/10/2017 | Q1 | -- | -- | $0.46 | -- | -- |
03/16/2017 | Q4 | -- | -- | -$0.05 | -- | -- |
11/03/2016 | Q3 | -- | -- | $0.30 | -- | -- |
08/11/2016 | Q2 | -- | -- | $0.26 | -- | -- |
05/17/2016 | Q1 | -- | -- | -$0.19 | -- | -- |
03/29/2016 | Q4 | -- | -- | -$0.16 | -- | -- |
11/09/2015 | Q3 | -- | -- | -$0.18 | -- | -- |
Lineage Cell Therapeutics reported $1.5M worth of top line sales in its most recent quarter.
Lineage Cell Therapeutics announced earnings per share of -$0.02 which represents a beat of analyst forecast a -$0.03 per share.
Lineage Cell Therapeutics reported $1.5M that represents $0.01 per share over the last quarter.
Lineage Cell Therapeutics's earnings are forecast to decrease from -$0.09 per share to -$0.11 per share next year representing a decrease of -16.67%.
Lineage Cell Therapeutics's next earnings date is August 8, 2025.
Signup to receive the latest stock alerts
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Market Cap: $4.2T
P/E Ratio: 58x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 35x
SharpLink Gaming [SBET] is down 2.6% over the past day.
Exodus Movement [EXOD] is down 4.14% over the past day.
Unity Software [U] is up 7.51% over the past day.